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ABSTRACT. As a continuation of our research and with the aim of obtaining new agents 
against Chagas disease, an extremely neglected disease which threatens 100 million people, 
eighteen new quinoxaline 1,4-di-N-oxide derivatives have been synthesized following the Beirut 
reaction. The synthesis of the new derivatives was optimized through the use of a new and more 
efficient microwave-assisted organic synthetic method. The new derivatives showed excellent in 
vitro biological activity against Trypanosoma cruzi. Compound 17, which was substituted with 
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fluoro groups at the 6- and 7-positions of the quinoxaline ring, was the most active and selective 
in the cytotoxicity assay. The electrochemical study showed that the most active compounds, 
which were substituted by electron-withdrawing groups, possessed a greater ease of reduction of 
the N-oxide groups.  
KEYWORDS: Chagas disease; Trypanosoma cruzi; quinoxaline 1,4-di-N-oxide; mutagenicity; 
cytotoxicity;  reduction  potential. 
1. INTRODUCTION 
Chagas disease or American trypanosomiasis was first described by Dr. Carlos Chagas in 1909. 
It is a chronic parasitosis caused by the haemoflagellated protozoan, Trypanosoma cruzi (T. 
cruzi), which is naturally transmitted by the triatomine hematophagous insect, Triatoma 
infestans. It is a major parasitic disease in Latin America, and it is endemic in 21 countries. [1-3] 
According to World Health Organization (WHO) data, Chagas disease affects about 8 million 
people and 100 million are at risk of infection, causing 13000 deaths annually. [4,5] In addition, 
it has an important socioeconomic impact on the endemic countries due to the fact that the 
chronic phase of the disease causes incapacity in infected people and due to the burden of high 
medical expenses placed upon the countries' governments. Moreover, in recent years, the 
incidence of the disease in non-endemic countries has increased due to new migration patterns. 
[6-8]  
Despite the fact that it has been more than 100 years since the disease has been discovered, safe 
and effective treatments have yet to be found. The largest decrease in the number of people 
affected is due to the control strategies carried out against the disease vector. [3, 9] Only two 
drugs have been commercialized, Nifurtimox (Nfx) and Benznidazole (Bzn), two nitroaromatic 
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heterocycles, empirically discovered over three decades ago. Both drugs have a number of 
limitations, such as low activity in the chronic phase of the disease, emergence of resistance, and 
toxicity. Therefore, there is an urgent need to develop new, safe and effective therapeutic 
alternatives that are also cost-effective. [10-13]  
Multiple anti-infective activities are well known for quinoxaline derivatives. [14, 15] Our group 
has vast experience in the synthesis and biological evaluation of multiple quinoxaline 1,4-di-N-
oxide derivatives, having identified a broad spectrum of anti-infective activities. [16-26] The 
evaluation of several libraries of compounds led us to find a series with high in vitro activity 
against T. cruzi. [27] This finding allowed us to establish structural features for maintaining high 
in vitro activity against the parasite (Scheme 1). 
Scheme 1 
Continuing with the optimization of the structure-activity scheme planned by our working group, 
eighteen new quinoxaline 1,4-di-N-oxide derivatives, series 1 (1-9) and series 2 (10-18) (Table 
2), were designed and synthesized. In order to carry out the synthesis, a traditional method and a 
new microwave-assisted method optimized by our group were used. The use of this new 
synthetic method was necessary due to the limitations encountered during the traditional 
synthesis. Microwave-assisted organic synthesis is an up-and-coming technique in medicinal 
chemistry and offers a number of important advantages. [28-31] The newly synthesized 
derivatives were modified at position 2 of the quinoxaline ring, possessing an ester group instead 
of a ketone group. These compounds were then evaluated against Tulahuen 2 strain of T. cruzi, 
using Nfx as the reference drug.  
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In previous works, the presence of the N-oxides significantly potentiated the activity against T. 
cruzi, which may indicate the importance of a bioreduction or metabolization process of these 
groups by specific enzymes within the activity of these types of derivatives. [18, 27, 32] 
However, the mechanism of action through which these derivatives carry out their activity is 
unclear. In previous studies, an inhibition of mitochondrial dehydrogenases was demonstrated 
and it was also observed that benzofuroxan derivatives containing N-oxide cause a mitochondrial 
membrane depolarization in T. cruzi. [27, 33, 34]  
In order to shed some light on this subject, a study was conducted which involved the measuring 
of the reduction potentials of the N-oxide groups in different synthesized derivatives and selected 
analogues. This experiment allowed us to conduct a study regarding the relationship between 
structure, N-oxides potential reduction and anti-T. cruzi activity. The aim of this study was to 
corroborate the importance of N-oxide reduction in biological activity and select the best 
substituents so as to find new leaders with higher activity and selectivity. 
To evaluate the preliminary toxicity profile of the new derivatives, the cytotoxicity, the 
selectivity against the parasites and the mutagenicity were studied. [35]  
2. RESULTS AND DISCUSSION 
2.1. CHEMISTRY 
Eighteen new quinoxaline 1,4-di-N-oxide derivatives were prepared using a variation of the 
Beirut reaction, in which the corresponding benzofuroxan (BFX) reacted with the appropriate 
trifluoroacetoacetate (INT) so as to obtain the target compounds (Scheme 2). In the derivatives 
from series 1 (1-9), a –CO2CH3 group was introduced into the 2-position of the quinoxaline ring 
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which was unsubstituted or substituted by different electronic substituents in the 6- and/or 7-
position of the heterocycle. Chloro, fluoro and trifluoromethyl were used as electron-
withdrawing groups, whereas methyl and methoxy were used as electron-donating groups.  
Scheme 2 
Derivatives of series 2 (10-18) possessed a –CO2CH2CH3 group in the 2-position and the same 
variety of substituents in the 6- and/or 7-positions of the heterocycle position as in series 1. The 
starting compounds, 5-substituted or 5,6-disubstituted BFXs, were obtained by previously 
described methods. [36] Commercial reagents were also used. The new derivatives were 
prepared using two different synthetic methods, as shown in Scheme 2. In the first, a traditional 
synthetic method normally used by our group in which the BFX reacts with INT using acetone as 
solvent and sodium carbonate as base at room temperature, was carried out (METHOD I). This 
synthetic method has several important limitations. Mainly low reaction yields, long reaction 
times and complex purification. We attempted to optimize the synthetic method by conducting 
the reaction at 40-50 ºC in an oil bath. However, with an increased temperature, the occurrence 
of by-products also increased, making purification difficult. Consequently, a new strategy of 
synthesis, microwave-assisted organic synthesis (MAOS), was attempted. A variation of Beirut 
reaction by microwaves irradiation, in which toluene was used as solvent and triethylamine 
(Et3N) as base, was performed (METHOD II) (Scheme 2).  
In order to determine if the microwave-assisted method offered advantages, the synthesis of nine 
of the new derivatives was performed in duplicate and two strategic parameters, reaction yield 
and reaction time, were compared. Compounds 6-8, 10-12 and 14-17 were synthesized using 
both of the proposed synthetic methods. As shown in Chart 1, the use of the new microwave-
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assisted synthesis method increased the reaction yields. The largest increase was observed in 
compound 16, where the yield increased more than 20 times, from 1% to 22%. The results 
suggest that derivatives with halogen substituents at positions 6 and/or 7 of the quinoxaline ring 
react better using the microwave method. 
The increase in yield was also influenced by easier purification method of the final product. 
Moreover, this resulted in a reduction of the quantity of solvent needed, with economic and 
environmental advantages.   
The new optimized microwave-assisted synthesis method also permitted significantly reduced 
reaction times. As can be observed in Table 1, the data indicate a huge decrease in reaction times 
when using microwave irradiation. For example, compound 12 requires seven days using the 
traditional method while the new microwave method reduces the time to 52 minutes, 
representing a decrease of almost 200 times in the required reaction time. These observed 
reductions in reaction times are a key advantage of the optimized microwave method compared 
to the traditionally used method. 
Chart 1 
Table 1 
2.2. IN VITRO ANTI-T. CRUZI ACTIVITY 
The in vitro activity evaluation of 18 new quinoxaline 1,4-di-N-oxide derivatives was carried out 
on the epimastigote form of T. cruzi. The selection of the epimastigote form of T. cruzi as an 
obligate mammalian intracellular stage has been re-evaluated and confirmed [37-39].  The results 
obtained are shown in table 2. The strain used was Tulahuen 2. The ability of each compound 
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(dose 25 μM) to inhibit the growth of the parasite (PGI) was evaluated and compared to the 
control (no drug added to the media) on day 5. For compounds showing high values of PGI, the 
50% inhibitory growth concentrations (IC50), were evaluated. In both assays, Nifurtimox (Nfx) 
was used as the reference drug. The PGI and the IC50 were calculated as indicated in the 
Experimental Section. Table 2 shows the PGI and IC50 results obtained for the 18 newly 
synthesized derivatives and the values for the reference drug, Nfx. The new derivatives showed 
potent in vitro activity against the Tulahuen 2 strain of T. cruzi: all of them presenting PGI 
values higher than 85%. Fourteen out of 18 compounds presented PGI values of 100% and 
sixteen out of 18 were more potent than the reference drug Nfx. Compound 17 was  identified as 
the most active, showing an IC50 value of 0.4 µM, 18 times more active than Nfx (7.7 µM).  
The results obtained permitted us to establish a series of structure-activity relationships with 
regard to the idealness of the substituents used in positions C-2, C-3, C-6 and C-7 of the 
quinoxaline ring. In addition, there is a clearly observed relationship between the electronic 
characteristics of substituents in the C-6 and/or C-7 of the quinoxaline ring and the in vitro 
biological activity obtained. As shown in Table 2, when substituents in C-6 and/or C-7 
possessed high electron-withdrawing characteristics, such as those in compounds 5, 8, 14-18, i.e. 
by chlorine, fluorine and trifluoromethyl, the biological activity increased, resulting in lower IC50 
values. However, when substituents in C-6 and/or C-7 had electron-releasing character, such as 
the CH3 group in compounds 3 and 13, the activity decreased.  
Within each series of compounds (1-9 and 10-18), the best results were obtained from the 
derivatives substituted by fluorine in C-6 and C-7 of the quinoxaline ring (compounds 8 and 17). 
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In order to carry out a study on the structure-activity relationships with respect to the substituents 
used in C-2 and C-3, Table 5 has been included in the supporting information. This Table 5 
shows the in vitro activity results of 19 quinoxaline 1,4-di-N-oxide derivatives, previously 
evaluated by our research group [27]. With respect to position C-3 of the quinoxaline ring, the 
introduction of the trifluoromethyl group is decisive in the in vitro biological activity shown by 
the derivatives with with-drawing substituents in C-6 and C-7; this is clearly observed upon 
comparing the activity of the new derivatives with the activity shown by the analogs with a 
methyl group or phenyl group in C-3 (A,L vs 13, E vs 1, D vs 4, O vs 11 and N vs 12, Tables 2 
and 5). However, this influence appears not to be as great in the derivatives substituted by 
chlorine, and especially by fluorine, in C-6 and C-7. We observed this in the results obtained 
from the analog compounds J, P and R, which show very good biological activity against T. cruzi 
and in C-3 they present methyl or phenyl, respectively. These data appear to indicate that the 
influence of the trifluoromethyl group on the activity depends on the electronic character of the 
substituents used in C-6 and C-7 of the quinoxaline ring. 
A similar explanation could be given for the rationale involved in the replacement of the ketone 
at C-2 [27] of quinoxaline ring by a methyl or an ethyl ester. The ester derivatives improve the 
biological activity of the corresponding ketone in every case with the exception of when the 
substituents in C-3, C-6 and C-7 are CF3, F and F respectively. 
Finally, with regard to the C-2 substituent, the influence of a methyl or ethyl group in 
determining the biological activity is not clear. Comparing the activity of the two series of new 
derivatives presented in our work (1-9 vs. 10-18), the presence of the ethyl ester group 
(compounds 10-18) slightly improves the in vitro activity results shown by the derivatives that 
possess the methyl ester group (compounds 1-9) with the exception of the derivatives without 
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substitutions (1 vs. 10) and in those that are substituted with CH3 at C-6 and C-7 of the 
quinoxaline ring (4 vs. 13).  
As our group had observed in previous works that we had carried out [27], it can be confirmed 
that the most decisive structural characteristic, in terms of in vitro biological activity, is the 
presence of substituents with an with-drawing character in positions 3, 6 and 7 of the quinoxaline 
ring, especially fluorine atoms. It is well-known that the introduction of fluorine atoms can 
modify the electronic, lipophilic and pharmacokinetic properties of drugs considerably. [40-42]  
Table 2 
2.3. CYTOTOXICITY IN MAMMALIAN CELLS 
Due to the excellent in vitro activity data against T. cruzi obtained for the 18 new compounds we 
decided to explore their in vitro cytotoxicity in mammalian cells using the MTT assay. The IC50 
values obtained and selective indexes (SI) calculated for 13 out of 18 new derivatives after 48 h 
of incubation are shown in Table 3. The selective indexes were calculated as the ratio of IC50 in 
macrophages to IC50 in T. cruzi Tulahuen 2 strain. Nfx data were previously reported. [43] As 
shown in Table 3, the newly synthesized compounds showed lower selectivity against the 
parasite than Nfx. The compounds 1 and 17 showed the highest selectivity against the parasite. 
In the conducted assay, cytotoxicity was determined from the function of mitochondrial 
dehydrogenases enzymes activity. Analogous compounds to those showed inhibitory capacity on 
these kinds of enzymes. [27] The significant effect observed on the cytotoxicity in the MTT 
assay could be related to mitochondrial dehydrogenases inhibitory activity.  
Table 3 
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2.4. AMES TEST: MUTAGENICITY 
The results obtained from the Ames test in S. typhimurium TA98 strain for compounds 1-18 with 
and without S9 activation are shown in Table 4. The evaluated doses of each compound were 
determined in previous solubility and toxicity studies on the test system. We observed that four 
of the eighteen tested derivatives (6, 9, 15 and 18) were not mutagenic in any of the two 
conditions tested, with or without S9 activation. Compounds 6 and 9 belong to the methyl-ester 
series and 15 and 18 to the ethyl-ester series. All of these four compounds have electron-
withdrawing substituents at C-6- and/or C-7 in the quinoxaline ring, with compounds 6 and 15 
being the 6,7-diCl derivatives and compounds 9 and 18 being the 7-CF3  derivatives.  
The other derivatives with electron-withdrawing substituents and the unsubstituted derivatives 
(compounds 5, 7, 8, 10, 12, 13, 14, 16 and 17) showed mutagenicity in the assay without 
metabolic activation. However, this mutagenicity disappeared when the assay was performed 
with metabolic activation.  
Derivatives 1-4 and 11, all possessing electron-releasing substituents (CH3O, CH3 and diCH3) at 
positions 6 and/or 7, exhibited mutagenicity in both conditions tested (-S9 and +S9).  
Derivatives with electron-withdrawing groups at the 6- and/or 7-positions either showed no 
mutagenicity or the mutagenicity would disappear after the derivatives were metabolized. On the 
other hand, derivatives with electron-releasing substituents in these same positions showed high 
mutagenicity, especially derivative 2, with a methoxy group at C-7. These results suggest a clear 
relationship between the mutagenicity observed in the Ames test and the electronic character of 
substituents at C-6- and/or C-7 of the quinoxaline ring.  
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Table 4 
2.5. ELECTROCHEMISTRY 
The redox properties of 16 quinoxaline derivatives between -0.4 and -2.6 V (vs Ag/AgNO3) were 
investigated using cyclic voltammetry in DMF with TBAP as supporting electrolyte. These 
compounds fall into two different categories: derivatives with a 3-methyl group (A, B and C) and 
derivatives with a 3-trifluoromethyl group (3-4, 6-12 and 14-17).  All redox potentials are 
reported versus the ferrocene/ferrocinium (Fc/Fc+) redox couple. All voltammetric reductions 
were found to be diffusion controlled, as indicated by fairly constant current functions at the 
different scan rates used in the study. [44, 45]     
The electrochemical reductions of various quinoxaline di-N-oxide derivatives in aprotic solvent 
systems have been reported previously. [46-52]. In the current study, several voltammetric waves 
were observed during cyclic voltammetry of the quinoxaline di-N-oxide derivatives between -0.4 
and -2.3 V. The first reduction process observed in the voltammograms may be attributed to 
reduction of the nitrone functionality, forming a radical anion (Figure 1). [46-52] 
Figure 1 
The influence of structure on reduction potential may be examined by comparison of the data 
found in Table 2. Substitution of an electron withdrawing group onto the quinoxaline ring at 
positions C-3 or C-7 causes a positive shift in reduction potential, making reduction more facile. 
For example, replacing the 7-hydrogen atom in compound 1 with the 7-fluoro group in 
compound 7 and the 7-trifluoromethyl group in compound 9 resulted in shifts in E1/2 of +0.102 V 
and +0.232 V, respectively. Likewise, replacing the 3-methyl group in compound C with the 3-
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trifluoromethyl group in compounds 6 and 15 resulted in a positive shift in E1/2 of +0.290 V and 
+0.285 V, respectively. Other examples may be observed by comparing compounds B vs. 12, 
and 10 vs. 14 vs. 16. In addition, substitution of a second electron-withdrawing group onto the 
quinoxaline ring at C-6 enhanced these effects (cf. 1 vs. 7 vs. 8, 10 vs. 14 vs. 15, 10 vs. 16 vs. 
17).   
Substitution of an electron donating group, i.e. methyl and methoxy, in these same positions on 
the quinoxaline ring causes a negative shift in reduction potential, i.e. reduction becomes more 
difficult. For example, replacing the 7-hydrogen atom in compound 10 with the 7-methyl group 
in derivative 12 and the 7-methoxy group in 11 resulted in shifts in E1/2 of -0.043 V and -0.076 
V, respectively. The results of the present study agree with previous electrochemical studies 
dealing with the effects of structure on the reduction potentials of quinoxaline di-N-oxide 
derivatives, [46-48, 50-52] and indicate that reduction is facilitated by a positive charge at the 
reaction site. [53]  
The influence of the substituent at R2, i.e. –CO2Me vs. –CO2Et, on potential appeared to be 
negligible, in agreement with a previous study. [51]  
The voltammetric results provide some pieces of information that may be important for 
understanding the mechanism of anti- T. cruzi activity for these compounds. The data suggest a 
possible relationship between ease of reduction and activity (Table 2). A plot of E1/2 versus PGI 
% is shown in Chart 2. The chart shows that there is not a direct correlation between reduction 
potential and activity. However, examination of the data shows that the compounds with 
reduction potentials more negative than -1.3 V tend to be generally less active. In fact, of the 
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seven compounds with E1/2 values lower than -1.3 V, five exhibit activities below a PGI of 
100%. 
The quinoxalines 1,4-di-N-oxide functionality could be activated through a bioreduction process 
which leads to the production of OH radicals or other oxy radical species and anionic active 
forms in the biological medium. If this is the case, bioreductive activation would generally be 
expected to be more facile for more easily reduced derivatives. In a previous study, we 
demonstrated that mitochondrial dehydrogenases are involved in the anti-T. cruzi activity of 
active quinoxaline-1,4-di-N-oxide-2-ketone derivatives, [27] indicating that redox behavior is 
important to the mechanism of action of the latter quinoxaline di-N-oxides. It is conceivable that 
a similar mechanism of action is involved with the quinoxaline 1,4-di-N-oxide-2-alkyl 
carboxylate derivatives.  However, exceptions in the data, represented by derivatives 11 and 12, 
indicate that factors besides bioreduction must also be considered in the mechanism of anti-T. 
cruzi action, i.e. absorption, membrane permeability, metabolism, solubility, and site binding, 
just to name a few examples. 
Chart 2 
3. CONCLUSIONS 
Eighteen new 1,4-di-N-oxide derivatives were synthesized using a variation of the Beirut 
reaction. A new synthetic method was optimized by microwave-assisted synthesis, providing an 
increase in reaction yields and a dramatic decline in the reaction times. The new derivatives 
showed high biological in vitro activity against T. cruzi, sixteen of which had greater in vitro 
efficacy against Tulahuen 2 strain than that of Nifurtimox. The importance of the presence of a 
trifluoromethyl group at the C-3 of the quinoxaline ring in the in vitro biological activity was 
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confirmed. Introduction of electron-withdrawing substituents at C-6 and/or C-7 of the 
quinoxaline ring enhanced in vitro biological activity against T. cruzi. In addition, this led to the 
obtainment of non-mutagenic derivatives in both the Ames assays that were performed or their 
mutagenicity disappeared when performing the assay using metabolic activation. In general, the 
selectivity shown by the new derivatives against the parasite could be improved. However, due 
to the inhibition exerted on mitochondrial dehydrogenases by related compounds and the 
characteristics of the MTT trial used, this issue will be discussed in depth in future trials.  
Furthermore, it was found that the presence of electron-withdrawing substituents facilitated the 
reduction process of the N-oxides: and compounds with less negative values of reduction 
potential generally showed greater efficacy against the parasite. These results suggested that a 
bioreduction process of the N-oxides might be taking place in the mechanism of action of these 
types of derivatives. Compound 17 was identified as the most active and showed the highest 
selectivity against the parasite. In addition, it was not mutagenic in the Ames test conducted with 
metabolic activation. 
The information obtained will be useful for the design of future derivatives with greater 
biological activities against T. cruzi and better toxicity profiles. 
4. EXPERIMENTAL SECTION   
4.1. SYNTHESIS 
All of the synthesized compounds were chemically characterized by melting point, thin layer 
chromatography (TLC), infrared spectroscopy (IR), proton nuclear magnetic resonance (1H 
NMR) and elemental microanalyses (CHN). 
 15
Melting points were determined with a Mettler FP82+FP80 apparatus (Greifense, Switzerland) 
and have not been corrected. The IR spectra were recorded on a Nicolet Nexus FTIR (Thermo, 
Madison, USA) using KBr pellets. The 1H NMR spectra were recorded on a Bruker 400 
Ultrashield instrument (400 MHz), using TMS as the internal standard and with CDCl3 as the 
solvent; the chemical shifts are reported in ppm () and coupling constant (J) values are given in 
Hertz (Hz). Signal multiplicities are represented by: s (singlet), d (doublet), dd (double doublet), 
ddd (doublet of double doublet), t (triplet), q (quadruplet) and m (multiplet). Elemental 
microanalyses were obtained on a CHN-900 Elemental Analyzer (Leco, Tres Cantos, Spain) 
from vacuum-dried samples. The analytical results for C, H and N, were within 0.4 of the 
theoretical values. 
Microwave-assisted synthesis was carried out with a Discover SP System reactor (CEM 
Corporation), using the SynergyTM software. 
Alugram SIL G/UV254 (Layer: 0.2 mm) (Macherey-Nagel GmbH & Co. KG., Düren, Germany) 
was used for TLC. Column chromatography was developed by Silica gel 60, with 0.040-0.063 
mm particle size (Merck, Darmstadt, Alemania).  
Chemicals were purchased from Panreac Química S.A. (Barcelona, Spain), Sigma-Aldrich 
Química, S.A. (Alcobendas, Spain), Acros Organics (Janssen Pharmaceuticalaan, Geel, Belgium) 
and Lancaster (Bischheim-Strasbourg, France). 
4.1.1. General procedure of the synthesis of 2-alkylcarbonyl-3-trifluoromethylquinoxaline-
1,4-di-N-oxide derivatives using K2CO3 (METHOD I). 
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The corresponding BFX (10 mmol) was dissolved in acetone (25 mL) and then cooled by placing 
it on ice. Next, 4,4,4-trifluoroacetoacetate (15 mmol) was added dropwise and K2CO3 (20 mmol) 
was added as the base. The reaction mixture was stirred at room temperature for 1-7 days, 
depending on the BFX substituents that were used. The product formation was checked out using 
TLC. Then the solvent was evaporated under reduced pressure. The obtained solid was dissolved 
in dichloromethane and washed with water in order to eliminate the catalyst salt. The organic 
phase was dried with anhydrous K2SO4 and then the solvent was evaporated under reduced 
pressure. The obtained oil was purified by column chromatography using dichloromethane as the 
eluent. The pure oil obtained was treated with diethyl ether and precipitated as a yellow solid. 
4.1.2. General procedure of the synthesis of 2-alkylcarbonyl-3-trifluoromethylquinoxaline-
1,4-di-N-oxide-derivatives using microwave-assisted method (METHOD II).  
The appropriate BFX (10 mmol) was dissolved in 15 mL of toluene in a microwave vessel (35 
mL). The mixture was cooled with ice. Next, 4,4,4-trifluoroacetoacetate (15 mmol) was added 
dropwise and finally Et3N (1.5 mL) was added dropwise as the base. The mixture reaction was 
inserted in the microwave reactor and then subjected to an optimized method: microwave 
irradiation at 60 W for 40-60 minutes, depending on the BFX substituents used, keeping the 
temperature at 70 ºC. Once the reaction time finished, formation of the product was observed by 
TLC. The solvent was then eliminated under reduced pressure. Brown oil was obtained and it 
was purified by column chromatography, using dichloromethane as eluent. The obtained pure oil 
was precipitated with diethyl ether and then filtered off.  
4.1.3. 2- Methoxycarbonyl-3-trifluoromethylquinoxaline-1,4-di-N-oxide (1) 
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Yield: 3%.  IR (KBr): 3108 (w, νC-H Ar), 1748 (s, νC=O), 1364 (s, νΝ-oxide), 1163 (m, νC-F). 
1H NMR (400 MHz, CDCl3) δ ppm: 8.63-8.57 (m, 2H, H5 + H8); 7.97-8.04 (m, 2H, H6 + H7); 
4.12 (s, 3H, CH3). Calc. Anal. for C11H7F3N2O4: C, 45.85%; H, 2.45%; N, 9.72%. Found: C, 
45.98%; H, 2.34%; N, 9.55%. 
4.1.4. 7-Methoxy-2-methoxycarbonyl-3-trifluoromethylquinoxaline-1,4-di-N-oxide (2) 
Yield: 4%.  IR (KBr): 3089 (w, νC-H Ar), 1739 (s, νC=O), 1354 (s, νN-oxide), 1261 (m, νC-O), 
1145 (m, νC-F). 1H NMR (400 MHz, CDCl3) δ ppm: 8.54 (d, 1H, H5, J5-6 = 9.3 Hz); 7.88 (d, 1H, 
H8, J8-6 = 2.3 Hz); 7.54 (dd, 1H, H6, J6-8 = 2.6 Hz, J6-5 = 9.3 Hz); 4.11 (d, 3H, CH3, JCH3-CF3 = 1.5 
Hz); 4.06 (s, 3H, CH3O). Calc. Anal. for C12H9F3N2O5: C, 45.28%; H, 2.83%; N, 8.80%. Found: 
C, 45.18%; H, 2.90%; N, 8.86%. 
4.1.5. 2-Methoxycarbonyl-7-methyl-3-trifluoromethylquinoxaline-1,4-di-N-oxide (3) 
Traditional yield: 8%.  IR (KBr): 3105 (w, νC-H Ar), 1735 (s, νC=O), 1355 (s, νN-oxide), 1274 
(m, νC-O), 1152 (m, νC-F). 1H NMR (400 MHz, CDCl3) δ ppm: 8.54 (d, 1H, H5, J5-6 = 8.6 Hz); 
8.40 (s, 1H, H8); 7.79 (d, 1H, H6, J6-5 = 8.6 Hz); 4.10 (s, 3H, CH3); 2.67 (s, 3H, CH3-C7). Calc. 
Anal. for C12H9F3N2O4: C, 47.69%; H, 3.00%; N, 9.27%. Found: C, 47.49%; H, 3.07%; N, 
9.13%. 
4.1.6. 2-Methoxycarbonyl-6,7-dimethyl-3-trifluoromethylquinoxaline-1,4-di-N-oxide (4) 
Traditional yield: 4%.  IR (KBr): 3090 (w, νC-H Ar), 1756 (s, νC=O), 1343 (s, νN-oxide), 1268 
(m, νC-O), 1174 (m, νC-F). 1H NMR (400 MHz, CDCl3) δppm: 8.38 (s, 1H, H5); 8.35 (s, 1H, 
H8); 4.10 (s, 3H, CH3); 2.57 (s, 6H, CH3-C6 + CH3-C7). Calc. Anal. for C13H11F3N2O4: C, 
49.38%; H, 3.51%; N, 8.86%. Found: C, 48.99%; H, 3.20%; N, 8.17%. 
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4.1.7. 7-Chloro-2-methoxycarbonyl-3-trifluoromethylquinoxaline-1,4-di-N-oxide (5) 
Yield: 22%.  IR (KBr): (w, νC-H Ar), (s, νC=O), (s, νN-oxide),  (m, νC-O), (m, νC-F). 1H NMR 
(400 MHz, CDCl3) δppm: 8.58 (d, 1H, H5, J5-6 = 9.0 Hz); 8.58 (d, 1H, H8, J8-6 = 2.0 Hz); 7.90 
(dd, 1H, H6, J6-5 = 9.3 Hz, J6-8 = 2.0 Hz); 4.0 (d, 3H, CH3, JCH3-CF3 = 1.5 Hz). Calc. Anal. for 
C11H6F3N2O4Cl: C, 40.95%; H, 1.87%; N, 8,68%. Found: C, 41.03%; H, 1.88%; N, 8.58%. 
4.1.8. 6,7-Dichloro-2-methoxycarbonyl-3-trifluoromethylquinoxaline-1,4-di-N-oxide (6) 
Yield: 4%.  IR (KBr): 3177 (w, νC-H Ar), 1756 (s, νC=O), 1339 (s, νN-oxide), 1278 (m, νC-O), 
1169 (m, νC-F). 1H NMR (400 MHz, CDCl3) δppm: 8.74 (s, 1H, H5); 8.71 (s, 1H, H8); 4.10 (s, 
3H, CH3). Calc. Anal. for C11H5Cl2F3N2O4: C, 36.97%; H, 1.4%; N, 7.84%. Found: C, 36.66%; 
H, 1.38%; N, 7.72%. 
4.1.9. 7-Fluoro-2-methoxycarbonyl-3-trifluoromethylquinoxaline-1,4-di-N-oxide (7) 
Yield: 25%.  IR (KBr): 3077 (w, νC-H Ar), 1756 (s, νC=O), 1340 (s, νN-oxide), 1278 (m, νC-O), 
1168 (m, νC-F). 1H NMR (400 MHz, CDCl3) δppm: 8.69 (dd, 1H, H5, J5-6 = 9.6 Hz, J5-F = 4.9 
Hz); 8.28 (dd, 1H, H8, J8-F = 8.0 Hz, J8-6 = 2.7 Hz); 7.72 (ddd, 1H, H6, J6-5 = 9.7 Hz, J6-F = 7.2 
Hz, J6-8 = 2.7 Hz); 4.12 (s, 3H, CH3). Calc. Anal. for C11H6F4N2O4: C, 43.15%; H, 1.98%; N, 
9.15%. Found: C, 43.18%; H, 1.84%; N, 8.85%. 
4.1.10. 6,7-Difluoro-2-methoxycarbonyl-3-trifluoromethylquinoxaline-1,4-di-N-oxide (8) 
Yield: 4%.  IR (KBr): 3066 (w, νC-H Ar), 1750 (s, νC=O), 1356 (s, νN-oxide), 1252 (m, νC-O), 
1187 (m, νC-F). 1H NMR (400 MHz, CDCl3) δppm: 8.47-8.39 (m, 2H, H5 + H8; 4.12 (d, 3H, 
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CH3). Calc. Anal. for C11H5F5N2O4: C, 40.70%; H, 1.55%; N, 8.64%. Found: C, 40.79%; H, 
1.35%; N, 8.54%. 
4.1.11. 2-Methoxycarbonyl-3,7-bis (trifluoromethyl) quinoxaline-1,4-di-N-oxide (9) 
Yield: 2%.  IR (KBr): 3108 (w, νC-H Ar), 1755 (s, νC=O), 1351 (s, νN-oxide), 1267 (m, νC-O), 
1170 (m, νC-F). 1H NMR (400 MHz, CDCl3) δ (ppm): 8.92 (d, 1H, H8, J8-6 = 1.8 Hz);  8.80 (d, 
1H, H5, J5-6 = 9.0 Hz);  8.18 (dd, 1H, H6, J6-5 = 9.0 Hz, J6-8 = 1.7 Hz); 4.12 (s, 3H, CH3). Calc. 
Anal. for C12H6F6N2O4: C, 40.45%; H, 1.68%; N, 7.86%. Found: C, 40.82%; H, 1.75%; N, 
7.73%. 
4.1.12. 2-Ethoxycarbonyl-3-trifluoromethylquinoxaline-1,4-di-N-oxide (10) 
Yield: 1%.  Microwave yield: 8%. IR (KBr): 3016 (w, νC-H Ar), 1744 (s, νC=O), 1360 (s, νN-
oxide), 1264 (m, νC-O), 1154 (m, νC-F). 1H NMR (400 MHz, CDCl3) δppm: 8.66-8.62 (m, 2H, 
H5 + H8); 7.97-8.03 (m, 2H, H6 + H7);  4.59 (q, 2H, CH2, JCH2-CH3 = 7.1 Hz); 1.47 (t, 3H, CH3, 
JCH3-CH2 = 7.1 Hz). Calc. Anal. for C12H9F3N2O4: C, 47.69%; H, 3.00%; N, 9.27%. Found: C, 
47.49%; H, 3.07%; N, 9.13%. 
4.1.13. 2-Ethoxycarbonyl-7-methoxy-3-trifluoromethylquinoxaline-1,4-di-N-oxide (11) 
Yield: 1%.  Microwave yield: 5%. IR (KBr): 3087 (w, νC-H Ar), 1742 (s, νC=O), 1356 (s, νN-
oxide), 1263 (m, νC-O), 1143 (m, νC-F). 1H NMR (400 MHz, CDCl3) δppm: 8.54 (d, 1H, H5, J5-
6 = 9.5 Hz); 7.89 (d, 1H, H8, J8-6 = 2.6 Hz); 7.53 (dd, 1H, H6, J6-8 = 2.7 Hz, J6-5 = 9.5 Hz); 4.59 (q, 
2H, CH2, JCH2-CH3 = 7.1 Hz); 4.05 (s, 3H, CH3O); 1.47 (t, 3H, CH3, JCH3-CH2 = 7.1 Hz). Calc. 
Anal. for C13H11F3N2O5: C, 46,98%; H, 3.31%; N, 8.43%. Found: C, 46.83%; H, 3.24%; N, 
8.14%. 
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4.1.14. 2-Ethoxycarbonyl-7-methyl-3-trifluoromethylquinoxaline-1,4-di-N-oxide (12) 
Yield: 1%.  Microwave yield: 4%. IR (KBr): 3096 (w, νC-H Ar), 1743 (s, νC=O), 1352 (s, νN-
oxide), 1271 (m, νC-O), 1153 (m, νC-F). 1H NMR (400 MHz, CDCl3) δppm: 8.53 (d, 1H, H5, J5-
6 = 8.8 Hz); 8.41 (s, 1H, H8); 7.78 (dd, 1H, H6, J6-5 = 8.9 Hz, J6-8 = 1.4 Hz); 4.58 (q, 2H, CH2, 
JCH2-CH3 = 7.1 Hz); 2.67 (s, 3H, CH3); 1.47 (t, 3H, CH3, JCH3-CH2 = 7.1 Hz). Calc. Anal. for 
C13H10F3N2O4: C, 49,36%; H, 3.48%; N, 8.86%. Found: C, 49.22%; H, 3.38%; N, 8.79%. 
4.1.15. 2-Ethoxycarbonyl-6,7-dimethyl-3-trifluoromethylquinoxaline-1,4-di-N-oxide (13) 
Yield: 1%. IR (KBr): 3068 (w, νC-H Ar), 1749 (s, νC=O), 1356 (s, νN-oxide), 1270 (m, νC-O), 
1175 (m, νC-F). 1H NMR (400 MHz, CDCl3) δppm: 8.38 (s, 1H, H5); 8.36 (s, 1H, H8); 4.58 (q, 
2H, CH2, JCH2-CH3 = 7.1 Hz); 2.57 (s, 6H, CH3-C6 + CH3-C7); 1.47 (t, 3H, CH3, JCH3-CH2 = 7.1 
Hz). Calc. Anal. for C14H13F3N2O4: C, 50.90%; H, 3.93%; N, 8.48%. Found: C, 51.09%; H, 
3.91%; N, 8.24%. 
4.1.16. 7-Chloro-2-ethoxycarbonyl-3-trifluoromethylquinoxaline-1,4-di-N-oxide (14) 
Yield: 8%.  IR (KBr): 3071 (w, νC-H Ar), 1749 (s, νC=O), 1355 (s, νN-oxide), 1267 (m, νC-O), 
1161 (m, νC-F). 1H NMR (400 MHz, CDCl3) δ (ppm): 8.61 (d, 1H, H8, J8-6 = 2.1 Hz); 8.59 (d, 
1H, H5, J5-6 = 9.2 Hz); 7.90 (dd, 1H, H6, J6-5= 9.2 Hz, J6-8 = 2.1 Hz); 4.59 (q, 2H, CH2, JCH2-CH3 = 
7.1 Hz); 1.47 (t, 3H, CH3, JCH3-CH2 = 7.1 Hz). Calc. Anal. for C12H8ClF3N2O4: C, 42.79%; H, 
2.37%; N, 8.32%. Found: C, 42.61%; H, 2.28%; N, 8.20%. 
4.1.17. 6,7-Dichloro-2-ethoxycarbonyl-3-trifluoromethylquinoxaline-1,4-di-N-oxide (15) 
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Yield: 3%.  Microwave yield: 31%. IR (KBr): 3081 (w, νC-H Ar), 1755 (s, νC=O), 1342 (s, νN-
oxide), 1269 (m, νC-O), 1171 (m, νC-F), 1022 (w, νar-Cl) . 1H NMR (400 MHz, CDCl3) δ 
(ppm): 8.74 (s, 1H, H5); 8.72 (s, 1H, H8); 4.58 (q, 2H, CH2, JCH2-CH3 = 7.1 Hz); 1.46 (t, 3H, CH3, 
JCH3-CH2 = 7.1 Hz). Calc. Anal. for C12H7Cl2F3N2O4: C, 38.81%; H, 1.88%; N, 7.54%. Found: C, 
38.67%; H, 1.87%; N, 7.39%. 
4.1.18. 2-Ethoxycarbonyl-7-fluoro-3-trifluoromethylquinoxaline-1,4-di-N-oxide (16) 
Yield: 1%.  Microwave yield: 22%. IR (KBr): 3119 (w, νC-H Ar), 1750 (s, νC=O), 1359 (s, νN-
oxide), 1267 (m, νC-O), 1171 (m, νC-F). 1H NMR (400 MHz, CDCl3) δ (ppm): 8.69 (dd, 1H, H5, 
J5-6 = 9.4 Hz, J5-F = 4.8 Hz); 8.28 (dd, 1H, H8, J8-F = 8.0 Hz, J8-6 = 2.6 Hz); 7.72 (ddd, 1H, H6, J6-F 
= 7.2 Hz, J6-8 = 2.6 Hz); 4.59 (q, 2H, CH2, JCH2-CH3 = 7.1 Hz); 1.47 (t, 3H, CH3, JCH3-CH2 = 7.1 
Hz). Calc. Anal. for C12H8F4N2O4: C, 45.00%; H, 2.50%; N, 8.75%. Found: C, 45.00%; H, 
2.41%; N, 8.63%. 
4.1.19. 2-Ethoxycarbonyl-6,7-difluoro-3-trifluoromethylquinoxaline-1,4-di-N-oxide (17) 
Yield: 10%.  IR (KBr): 3048 (w, νC-H Ar), 1745 (s, νC=O), 1354 (s, νN-oxide), 1253 (m, νC-O), 
1182 (m, νC-F). 1H NMR (400 MHz, CDCl3) δ (ppm): 8.46 (dd, 1H, H5, J5-F6 = 6.3 Hz, J5-F7 = 
4.3 Hz,); 8.43 (dd, 1H, H8, J8-F7= 6.4 Hz, J8-F6 = 4.3 Hz); 4.58 (q, 2H, CH2, JCH2-CH3 = 7.1 Hz); 
1.47 (t, 3H, CH3, JCH3-CH2 = 7.1 Hz). Calc. Anal. for C12H7F5N2O4: C, 42.60%; H, 2.07%; N, 
8.28%. Found: C, 42.59%; H, 1.97%; N, 8.16%. 
4.1.20. 2-Ethoxycarbonyl-3,7-bis (trifluoromethyl) quinoxaline-1,4-di-N-oxide (18) 
Yield: 2%.  IR (KBr): 3112 (w, νC-H Ar), 1750 (s, νC=O), 1350 (s, νN-oxide), 1268 (m, νC-O), 
1159 (m, νC-F), 1118 (m, νC-F). 1H NMR (400 MHz, CDCl3) δ (ppm): 8.93 (s, 1H, H8);  8.79 (d, 
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1H, H5, J5-6 = 9.0 Hz);  8.16 (dd, 1H, H6, J6-5 = 9.0 Hz, J6-8 = 1.4 Hz,); 4.60 (q, 2H, CH2, JCH2-CH3 
= 7.1 Hz); 1.47 (t, 3H, CH3, JCH3-CH2 = 7.1 Hz). Calc. Anal. for C13H8F6N2O4: C, 42.16%; H, 
2.16%; N, 7.56%. Found: C, 42.21%; H, 1.96%; N, 7.49%. 
4.2. IN VITRO ANTI-T. CRUZI TULAHUEN 2 STRAIN ASSAY  
T. cruzi Tulahuen 2 strain epimastigotes were grown at 28 °C in an axenic medium (BHI-
tryptose) as previously described, [19-21, 54-57] complemented with 5% fetal bovine serum. 
Epimastigotes from a 10-day-old culture (stationary phase) were inoculated into 50 mL of fresh 
culture medium in order to give an initial concentration of 1 × 106 cells/mL. Cell growth was 
followed by measuring the absorbance of the culture at 600 nm every day. Before inoculation, 
the media was supplemented with a given amount of the drug from a stock solution in DMSO 
(25 µM). The final concentration of DMSO in the culture medium never exceeded 0.4%, and the 
control was run in the presence of 0.4% DMSO and in the absence of drugs.  
The percentage of inhibition (PGI) was calculated as follows: PGI (%) = {1-[(Ap - A0p)/(Ac - 
A0c)]} × 100, where Ap = A600 of the culture containing the drug on day 5, A0p = A600 of the 
culture containing the drug just after addition of the inocula (day 0), Ac = A600 of the culture in 
the absence of drugs (control) on day 5, and A0c = A600 in the absence of the drug on day 0. 
In order to determine IC50 values, 50% inhibitory concentrations, parasite growth was followed 
in the absence (control) and in the presence of a range of concentrations of the corresponding 
drug. On day 5, the absorbance of the culture was measured and related to the control. The IC50 
value was taken as the concentration of drug needed to reduce the absorbance ratio to 50%. 
4.3. CYTOTOXICITY IN MAMMALIAN CELLS 
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J-774 murine macrophage-like cells (ATCC, USA) were maintained by passage in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 4 mM L-glutamine, and supplemented with 10% 
heatinactivated fetal calf serum and 1% of antibiotics (10,000 U/mL penicillin and 10,000 lg/mL 
streptomycin). J-774 cells were seeded (1 × 105 cells/ well) in 96 well microplates with 200 µL 
of RPMI 1640 medium supplemented with 20% heat-inactivated fetal calf serum. Cells were 
allowed to attach for 48 h in a humidified 5% CO2/95% air atmosphere at 37 ºC and, then, 
exposed to compounds (100.0–400.0 µM) for 48 h. Afterwards, cell viability was assessed by 
measuring the mitochondrial-dependent reduction of MTT (Sigma) to formazan. For that 
purpose, MTT was added to cells to a final concentration 0.4 mg/ mL and cells were incubated at 
37 ºC for 3 h. After removing the media, formazan crystals were dissolved in DMSO (180 µL), 
and the absorbance at 595 nm was read using a microplate spectrophotometer. Cytotoxicity 
percentages (% C) were determined as follows: % C = [100- (ODd - ODdm)/(ODc - ODcm)] x 100, 
where ODd is the mean of OD595 of wells with macrophages and different concentrations of the 
compounds; ODdm is the mean of OD595 of wells with different compound concentrations in the 
medium; ODc is the growth control and ODcm is the mean of OD595 of wells with medium only. 
Results are expressed as IC50 (compound concentration that reduce 50% control absorbance at 
595 nm). Every IC50 is the average of three different experiments. The selectivity indexes, SI, 
were expressed as the ratio between IC50 in macrophages and IC50 in T. cruzi (Tulahuen 2 strain). 
[58, 59]  
4.4. MUTAGENICITY ASSAY 
The preliminary Salmonella mutagenicity assay (Ames assay) was performed according to the 
method described earlier and following the OECD (Organisation for Economic Co-operation and 
Development) guideline 471 (Bacterial reverse mutation test) but only in S. typhimurium His-, 
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TA98 strain. [35, 60-62] Prior to starting the assay, the concentrations to be tested were selected 
in terms of solubility and toxicity results in the test system. For the mutagenicity test, a 
suspension of 2×109 S. typhimurium/mL was prepared and the treatment procedure with the 
different compounds was performed both with and without S9 mix as an external enzymatic 
metabolizing system. Rat liver S9, of commercial origin, was prepared as described earlier. [35] 
S9 fraction contains cytochrome P450 isoform enzymes, which are involved in drug metabolism 
and other enzyme activities. [63] In order to perform the assay without metabolic activation, the 
following was mixed in test tubes: 50 µL of each test compound solution, 500 µL of PBS (0.1 M, 
pH 7.4) and 100 µL of bacterial suspension. Once each compound was mixed, it was incubated 
for 1 hour at 37ºC and then 2 mL of molten top agar supplemented with histidine and biotin 
traces (0.05 mM each) were added. The mixture was vortexed immediately and then poured onto 
glucose minimal (GM) agar plates. 
The assay with metabolic activation was performed following the same procedure but replacing 
the 500 µL of PBS by 500 µL of S9 mix (10%, v/v S9, 4.7 mM NADP, 6mM d-glucose-6-
phosphate, 19 mM MgCl2, 36 mM KCl, phosphate buffer 0.1 M, pH 7.4). 
When the top agar had solidified, the plates were incubated in an inverted position in an 
incubator at 37ºC for 48 h. After this time had elapsed, the histidine revertant colonies were 
counted. 
 The test always used a negative control (solvent control), in which the solvent (DMSO) was 
added without compound, giving us the basal spontaneous mutation rate and two positive 
controls, 4-O-nitrophenylendiamine (NPD) without metabolic activation and 2-aminofluorene 
(2-AF) with metabolic activation. In addition, a bacterial control was carried out in order to 
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verify correct growing, and a phenotype control was carried out in order to assure that work was 
actually being carried out with the TA98 strain. 
For all the assays, the data were analyzed using the modified 2-fold rule in which a response was 
considered to be positive if the average response for at least two consecutive dose levels was 
more than twice the spontaneous frequencies and a dose-response relationship is observed. [64]  
4.5. ELECTROCHEMICAL STUDIES   
Cyclic voltammetric measurements were performed with a CHI Instruments 630 Voltammetric 
Analyzer using scan rates ranging from 50 mV/s to 1000 mV/s. Solution resistance was 
uncompensated. The electrochemical cell consisted of a Pt-disk (1.6 mm diameter) working 
electrode, a Pt-wire auxilliary electrode, and a Ag/AgNO3 (0.1 M in acetonitrile) reference 
electrode. All test solutions contained 1 mM of the particular quinoxaline compound and 0.10 M 
tetrabutylammonium perchlorate (TBAP) as supporting electrolyte. Deoxygenation of test 
solutions was carried out by passing a gentle and constant stream of prepurified dinitrogen 
through the solution for 15 minutes. The quinoxaline compound was added to the solution during 
the deoxygenation and allowed to dissolve. A blanket of dinitrogen was maintained over the 
solution during all experiments. Half-wave potentials and the difference in peak potentials were 
calculated using the following equations, [44] respectively: E1/2 = (Epa + Epc)/2 and Ep = Epa – 
Epc. Ferrocene (Fc) was used as an internal reference redox system to account for daily variations 
in the reference electrode and liquid junction potentials. [65] Fc (1 mM) was added to each 
solution after the voltammetric measurements of the test quinoxaline compound were complete. 
[66] All potentials are reported versus the ferrocene/ferrocinium (Fc/Fc+) redox couple, i.e. Epc, 
SRE – E1/2, Fc/Fc+ or E1/2, SRE – E1/2, Fc/Fc+. Half-wave potentials (E1/2) for ferrocene varied from 
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0.0050 V to 0.022 V during the course of this study. Dimethylformamide (DMF) (Fisher 
Scientific) was used as the solvent. TBAP and ferrocene were obtained from Aldrich Chemical 
Company. All reagents were obtained in the highest purity available and used without further 
purification. 
 
Supporting information available: Cyclic voltammetry data obtained for the quinoxaline 1,4-
di-N-oxide derivatives studied derivatives.  
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Figure legends 
 
Figure 1. One electron reduction of quinoxaline 1,4-di-N-oxides to form a radical anion. 
 
Scheme 1. Structure-activity relationships observed and used for the design of novel derivatives. 
 
Scheme 2. Synthetic procedures used to prepare compounds 1-18: (I) K2CO3, acetone, room 
temperature. (II) Et3N, toluene, microwave assisted method (60 W, 40-60 min, 70ºC). 
 
Chart 1. Comparison of reaction yields, after purification, obtained by synthetic methods I and 
II. 
 
Chart 2. Plot of reduction potentials (E1/2 vs. Fc/Fc+) for the first voltammetric wave of 
quinoxaline 1,4-di-N-oxide-2-alkyl carboxylates against the percentage of growth inhibition 
(PGI%). 
 37
 
Table 1. Comparison of reaction times obtained by synthetic methods I and II. 
 
Table 2. Structure, anti-T. cruzi activity and cyclic voltammetry data of quinoxaline derivatives.  
 
Table 3. Biological characterization of new Quinoxaline 1,4-di-N-oxide  against Mammal 
Macrophages 
Table 4.  Revertants in Salmonella typhimurium TA98 strain treated with different doses of 
compounds 1–18 for the two different treatment procedures (-S9 and +S9).  
 
Figure 1
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Scheme 1 
 
Scheme 2 
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Chart 1 
 
 
Chart 2 
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Table 1 
 
 
 
 
 
 
 
 REACTION TIMES 
COMP. METHOD I METHOD II
6 1 day 50 min 
7 2 day 50 min 
8 1 day 60 min 
10 3 day 50 min 
11 4 day   70 min 
12 7 day 52 min 
14 1 day 65 min 
15 1 day 65 min 
16 15 h 50 min 
17 1 day 50 min 
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Table 2 
 
 
Anti-T. cruzi 
activity 
 
Cyclic 
voltammetry 
Code -R2 -R3 -R6 -R7 PGIa 
(%) 
IC50 
(µM)b 
 E1/2 (V) 
Ad -CH2CH3 -CH3 -CH3 -CH3 1 -  -1.677 
Bd -CH2CH3 -CH3 -Cl -Cl 32 -  -1.370 
Cd -CH3 -CH3 -Cl -Cl 66 -  -1.366 
1 -CH3 -CF3 -H -H 100.0 2.6  -1.313 
2 -CH3 -CF3 -H -CH3O 86.6 4.6  N. D.c 
3 -CH3 -CF3 -H -CH3 96.1 13.7  N. D.c 
4 -CH3 -CF3 -CH3 -CH3 91.6 5.0  -1.359 
5 -CH3 -CF3 -H -Cl 100.0 1.8  N. D.c 
6 -CH3 -CF3 -Cl -Cl 100.0 10.8  -1.076 
7 -CH3 -CF3 -H -F 100.0 3.5  -1.211 
8 -CH3 -CF3 -F -F 100.0 1.5  -1.160 
9 -CH3 -CF3 -H -CF3 100.0 5.0  -1.081 
10 -CH2CH3 -CF3 -H -H 100.0 4.0  -1.281 
11 -CH2CH3 -CF3 -H -CH3O 100.0 4.8  -1.357 
12 -CH2CH3 -CF3 -H -CH3 100.0 4.8  -1.324 
13 -CH2CH3 -CF3 -CH3 -CH3 87.5 7.6  N. D.c 
14 -CH2CH3 -CF3 -H -Cl 100.0 1.8  -1.174 
15 -CH2CH3 -CF3 -Cl -Cl 100.0 2.9  -1.081 
 42
 
aPercentage of growth inhibition. Inhibition of epimastigote growth of Tulahuen 2 strain, dose = 
25 μM. The results are the mean of three independent experiments with a SD less than 10% in all 
cases. 
bIC50: concentration (in µM) that inhibits 50% of epimastigote form of T. cruzi growth. The 
results are the mean of three independent experiments with a SD less than 10% in all cases. 
cNot determined. 
dCompounds previously published (Journal of medicinal chemistry 2011, 54 (10), 3624-36). 
  
16 -CH2CH3 -CF3 -H -F 100.0 3.3  -1.216 
17 -CH2CH3 -CF3 -F -F 100.0 0.4  -1.161 
18 -CH2CH3 -CF3 -H -CF3 100.0 1.0  N .D.c 
Nifurtimox   100.0 7.7   
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Table 3 
 
 
 
Cytotoxicity 
Code -R2 -R3 -R6 -R7  IC50 
(µM)a 
SIb 
1 -CH3 -CF3 -H -H  19.0 7.3 
3 -CH3 -CF3 -H -CH3  4.0 0.3 
4 -CH3 -CF3 -CH3 -CH3  4.0 0.8 
6 -CH3 -CF3 -Cl -Cl  0.5 < 0.1 
7 -CH3 -CF3 -H -F  2.5 0.7 
9 -CH3 -CF3 -H -CF3  4.0 0.8 
10 -CH2CH3 -CF3 -H -H  4.0 1.0 
11 -CH2CH3 -CF3 -H -CH3O  6.0 1.2 
12 -CH2CH3 -CF3 -H -CH3  7.0 1.4 
13 -CH2CH3 -CF3 -CH3 -CH3  4.0 0.5 
16 -CH2CH3 -CF3 -H -F  0.5 0.1 
17 -CH2CH3 -CF3 -F -F  4.0 10 
18 -CH2CH3 -CF3 -H -CF3  4.2 4.2 
Nifurtimoxc    316.0 41.0 
aIC50: concentration (in µM) that inhibits 50% of J-774 murine macrophage-like cells growth 
after 48 h of incubation. The results are the mean of three independent experiments with a SD 
less than 10% in all cases. 
bSelectivity index :expressed as the ratio of IC50 in macrophages to IC50 in T. cruzi Tulahuen 2 
strain.  
cData from Bioorganic & medicinal chemistry 2007, 15 (7), 2768-81.  
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Table 4 
 
  N. R.b   N. R.b     
Comp Da -S9 +S9 Comp Da -S9 +S9 Comp Da -S9 +S9 
1 
 
(+) 
0.0 
0.06 
0.18 
0.5 
1.6 
5 
27±7 
17±4 
25±5 
33±8 
118±11 
227±79 
28±7 
17±3 
25±5 
30±9 
45±2 
84±15 
7 
 
(+)* 
0.0 
0.3 
0.92 
2.7 
8.3 
25 
27±7 
15±7 
20±4 
39±15 
115±5 
158±28 
28±7 
22±7 
22±9 
27±7 
27±4 
41±11 
13 
 
(+)* 
0.0 
0.06 
0.18 
0.5 
1.6 
12.5 
29±1 
25±4 
40±14 
57±2 
174±12 
352±11 
30±7 
32±3 
37±9 
45±5 
38±1 
71±10 
2 
 
(+) 
0.0 
0.3 
0.92 
2.7 
8.3 
25 
29±1 
29±4 
47±8 
70±6 
285±10 
379±31 
28±4 
31±4 
41±2 
66±6 
245±15 
680±17 
8 
 
(+)* 
0.0 
0.06 
0.18 
0.5 
1.6 
5 
29±1 
30±9 
33±2 
45±1 
118±17 
247±34 
28±4 
31±3 
34±9 
30±5 
29±7 
33±3 
14 
 
(+)* 
0.0 
0.06 
0.18 
0.5 
1.6 
5 
13±2 
14±4 
11±3 
20±1 
31±4 
55±11 
30±7 
32±3 
37±9 
45±5 
38±1 
71±10 
3 
 
(+) 
0.0 
0.06 
0.18 
0.5 
1.6 
5 
13±2 
15±1 
21±2 
26±11 
79±9 
136±24 
19±3 
15±4 
13±1 
16±1 
29±5 
100±8 
9 
 
(-) 
0.0 
0.06 
0.18 
0.5 
1.6 
5 
27±7 
25±4 
23±3 
24±2 
24±5 
25±1 
28±8 
25±2 
26±11 
25±9 
20±6 
41±15 
15 
 
(-) 
0.0 
0.06 
0.18 
0.5 
1.6 
5 
29±1 
29±1 
27±5 
29±1 
32±4 
37±1 
29±1 
30±7 
31±13 
27±3 
25±4 
34±7 
4 
 
(+) 
0.0 
0.61 
1.85 
5.5 
16.6 
50 
13±2 
10±1 
18±12 
22±6 
53±8 
73±12 
19±3 
18±2 
19±4 
16±1 
74±11 
260±23 
10 
 
(+)* 
0.0 
0.06 
0.18 
0.5 
1.6 
5 
29±1 
32±1 
31±12 
45±4 
109±8 
237±6 
28±4 
31±7 
36±4 
29±5 
27±2 
44±5 
16 
 
(+)* 
0.0 
0.06 
0.18 
0.5 
1.6 
5 
27±7 
16±1 
24±7 
42±2 
80±9 
152±43 
28±8 
24±1 
23±5 
28±5 
30±5 
25±5 
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5 
 
(+)* 
0.0 
1.2 x10-3 
3.7 x10-3 
0.011 
0.033 
5 
27±7 
19±1 
21±5 
20±1 
40±8 
109±17 
28±8 
22±2 
20±1 
24±3 
24±4 
33±4 
11 
 
(+) 
0.0 
0.3 
0.92 
2.7 
8.3 
25 
27±7 
15±1 
25±2 
40±9 
133±20 
188±51 
28±8 
24±3 
25±10 
30±5 
36±1 
169±24 
17 
 
(+)* 
0.0 
0.06 
0.18 
0.5 
1.6 
5 
13±2 
13±3 
10±5 
16±7 
33±2 
64±6 
19±3 
17±2 
17±2 
21±1 
18±3 
21±4 
6 
 
(-) 
0.0 
0.012 
0.037 
0.11 
0.33 
1 
13±2 
17±7 
27±1 
14±7 
26±2 
39±11 
19±3 
17±1 
22±9 
29±14 
17±4 
19±4 
12 
 
(+)* 
0.0 
0.3 
0.92 
2.7 
8.3 
25 
29±1 
33±12 
56±5 
90±1 
287±28 
352±3 
28±4 
38±7 
36±4 
41±3 
42±6 
71±18 
18 
 
(-) 
0.0 
0.06 
0.18 
0.5 
1.6 
12.5 
29±1 
25±3 
33±5 
31±8 
39±10 
39±7 
30±7 
39±2 
35±3 
32±7 
37±4 
32±7 
Nfxc 
 
(+) 
0.0 
0.5 
1.0 
3.0 
10.0 
30.0 
21±4 
29±6 
43±17 
62±2 
144±11 
117±17 
31±10 
37±5 
39±18 
53±9 
64±6 
139±11 
 
 
aD: Doses in µg/plate. bN.R.: Number of revertants. cData from Toxicology letters 2009, 190 (2), 
140-9. 
(+): Mutagenic. (-): Not mutagenic. *Mutagenic without metabolic activation and not mutagenic 
with metabolic activation. 
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Eighteen new quinoxaline 1,4-di-N-oxide derivatives have been synthesized and they have shown excellent in vitro 
biological activity against Trypanosoma cruzi, identifying one of the compounds as the most active and selective in 
the cytotoxicity assay. 
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PGI: % Inhibition of epimastigote growth of Tulahuen 2 strain. IC50: concentration that inhibits 50% of epimastigote 
form of T. cruzi growth. SI: Selectivity Index. 
 
